Laekna Therapeutics Shanghai Co. Ltd.

A top-line hit for AstraZeneca’s Truqap in a genetically defined subset of prostate cancer patients goes some way to make up for the AKT inhibitor’s failure and subsequent discontinuation in first-l

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

In gaining the first US approval for an AKT inhibitor in Truqap (capivasertib), AstraZeneca PLC has comprehensively trounced Roche Holding AG , whose similarly-acting ipatasertib once looked like a

AstraZeneca PLC has produced positive topline breast cancer data for two of its novel pipeline candidates – the AKT inhibitor capivasertib and the next-generation SERD camizestrant – with both antica